John Bothos

机构：Vividion Therapeutics (United States), AstraZeneca (United States)

发表论文 44 篇 · 总被引 1135 次 · h-index 12

代表论文

• Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide (2021 · Clinical Cancer Research · 被引 54)
• LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC (2021 · Annals of Oncology · 被引 21)
• ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study (2024 · Targeted Oncology · 被引 12)
• MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide. (2020 · Journal of Clinical Oncology · 被引 11)
• P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (2019 · Journal of Thoracic Oncology · 被引 4)
• A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome (2025 · Annals of Hematology · 被引 3)